Influenza and Other Respiratory Viruses最新文献

{"title":"Influenza in Adults Seeking Care at Seven European Emergency Departments: A Prospective Active Surveillance During the 2019–2020 Influenza Season","authors":"Sélilah Amour,&nbsp;Alberto Perez Rubio,&nbsp;Andrea Orsi,&nbsp;Michael Oppert,&nbsp;Micha Loebermann,&nbsp;Carlos del Pozo Vegas,&nbsp;Karim Tazarourte,&nbsp;Marion Douplat,&nbsp;Laurent Jacquin,&nbsp;Giancarlo Icardi,&nbsp;Jonas Walker,&nbsp;Andrea Glass,&nbsp;Joshua Nealon,&nbsp;Sandra S. Chaves,&nbsp;FERS Study Group,&nbsp;Hélène Bricout,&nbsp;Philippe Vanhems","doi":"10.1111/irv.70040","DOIUrl":"https://doi.org/10.1111/irv.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Influenza can be associated with nonrespiratory disease presentation, but these are less well documented due to the lack of routine testing for influenza in the healthcare system, especially if patients do not present with influenza-like illness (ILI). We aimed to measure the proportion of influenza cases seeking care at emergency department (ED) for a nontraumatic cause, to describe their clinical presentation and their ED-discharge diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study was conducted at seven hospitals in France, Spain, Italy and Germany during the 2019–20 influenza season, for a period of 10 weeks. Patients (≥ 18 years) consulting for nontraumatic causes at the ED were invited to participate. Consenting patients provided upper respiratory swab samples for influenza testing by reverse transcription polymerase chain reaction. Clinical and demographic data were collected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 8678 patients included, 50.7% were female and the median age was 57 years. Among them, 494 (5.7%) were laboratory-confirmed influenza (LCI) cases. Nonetheless, only 24.3% of LCI cases had an ED-discharge of influenza. Of all cases confirmed as influenza, 47.6% had a nonrespiratory discharge diagnosis, which frequency increased with age. ILI case definition from the European Centre for Disease Prevention and Control was the most frequently met among influenza cases (68.6%). Older patients (≥ 65 years) were less frequently identified based on any ILI signs/symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings indicate that the impact of influenza among patients seeking care at the ED cannot be easily assessed based on clinical presentation and medical records alone. Preventing influenza among adult population may reduce healthcare utilization.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70040","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS-CoV-2 in Africa: A Systematic Review","authors":"Kimberly Cheryl Chido Konono,&nbsp;Keiko Msusa,&nbsp;Samuel Mpinganjira,&nbsp;Adidja Amani,&nbsp;Charles Nyagupe,&nbsp;Michael Ngigi","doi":"10.1111/irv.70047","DOIUrl":"https://doi.org/10.1111/irv.70047","url":null,"abstract":"<p>The Global Initiative on Sharing All Influenza Data, a public-access database for sharing severe acute respiratory syndrome coronavirus 2 genomic sequencing data, has received significantly less data from African countries compared to the global total. Furthermore, the contribution of these data was infrequent and, for some countries, non-existent. The primary aim of this review is to identify the technological barriers to routine genomic surveillance in Africa. PubMed and Google Scholar were searched for the relevant articles, and other eligible articles were identified from the reference list examination according to the PRISMA checklist. Eighty-four full-text articles were analysed for eligibility, and 49 published full-texted articles were included in the final qualitative analysis. The main technological barriers identified were limited genomic surveillance capacity, limited genomic sequencing infrastructure, lack of resources and skilled or trained scientists, and the high cost of importing, establishing, and maintaining a genomic sequencing facility. The Africa Pathogen Genomics Initiative aims to improve genomic surveillance capacity across Africa, through resources, training, education, infrastructure, and regional sequencing centres. Furthermore, collaborations between African governments and international partners or national, private, and academic institutions are imperative to sustain genomic surveillance in Africa, and investment in genomic sequencing and research and development is paramount. Longer turnaround times interfere with global viral evolution monitoring and national implementation of effective policies to reduce the burden and disease. Establishing effective genomic surveillance systems guides public health responses and vaccine development for diseases endemic in Africa.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142665817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season","authors":"Takeyuki Goto,&nbsp;Naoki Kawai,&nbsp;Takuma Bando,&nbsp;Yoshio Takasaki,&nbsp;Shizuo Shindo,&nbsp;Tomonori Sato,&nbsp;Naoki Tani,&nbsp;Yong Chong,&nbsp;Hideyuki Ikematsu","doi":"10.1111/irv.70042","DOIUrl":"https://doi.org/10.1111/irv.70042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Clinical data on patients infected with influenza B Victoria (BV) after the approval of baloxavir is lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This observational study of the Japanese 2023–2024 influenza season analyzed data from 25 outpatients with A(H1N1)pdm09, 36 with A(H3N2), and 65 with BV. Viral samples were collected before and after administering an antiviral (70 patients received baloxavir and 56 received a neuraminidase inhibitor), on days 1, 5, and 10. Isolated viruses after culturing were amplified using RT-PCR and sequenced to detect mutations of concern, including acidic protein (PA)-amino acid (AA) E23X/I38X for influenza A and M34X/I38X for BV. Fever and symptoms were tracked via self-reporting diaries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No PA-AA-substituted virus was detected from 126 pre-treatment samples. In the baloxavir cohort, one (7.1%, 1/14) PA I38F-substituted A(H1N1)pdm09 and two (11.1%, 2/18) PA I38T-substituted A(H3N2) viruses were isolated on day 5 but not on day 10. No (0%, 0/37) PA-AA-substituted BV was detected on day 5 or after. The virus isolation rate on day 5 was higher among patients with BV than with influenza A in both baloxavir (35.1% vs. 14.3% for A(H1N1)pdm09 and 16.7% for A(H3N2)) and oseltamivir-treated patients (44.4% vs. 0% for A(H1N1)pdm09 and 33.3% for A(H3N2)). Patients with PA-AA-substituted influenza A after baloxavir administration did not have longer fever duration than those without virus isolation or with wild-type virus on day 5, for both A(H1N1)pdm09 and A(H3N2).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Baloxavir-resistant variants were not detected in influenza BV before treatment, as with A. The emergence of PA-AA-substituted influenza A after baloxavir administration was temporal and did not cause prolonged symptoms. No baloxavir-resistant BV variants were observed after baloxavir administration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142665818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Age and Comorbid Conditions on Incidence Rates of COVID-19-Associated Hospitalizations, 2020–2021","authors":"Lisa Saiman,&nbsp;Edward E. Walsh,&nbsp;Angela R. Branche,&nbsp;Angela Barrett,&nbsp;Luis Alba,&nbsp;Sonia Gollerkeri,&nbsp;Julia A. Schillinger,&nbsp;Matthew Phillips,&nbsp;Lyn Finelli","doi":"10.1111/irv.70016","DOIUrl":"10.1111/irv.70016","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>COVID-19-associated hospitalization rates by age and comorbid conditions can more precisely assess risk for severe illness and target prevention and treatment strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a retrospective study to estimate population-based COVID-19-associated hospitalization among patients by age and selected comorbid conditions in three hospital systems in Rochester and New York City (NYC), NY. Incidence rate ratios (IRR) comparing incidence rates for patients with and without these comorbidities were determined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From March 2020 to December 2021, 7779 patients were hospitalized with COVID-19 of whom 43.8% had ≥3 comorbid conditions. Overall annual incidence ranged from 325.3 to 965.8 per 100,000 persons. Age group-specific incidence was lowest in children 10–14 years (range 4.4–58.9) and highest in adults ≥85 years (range 2790.5–5889.6). Incidence rates for comorbid conditions generally increased with increasing age while IRR decreased with increasing age. Children in NYC 5–17 years with asthma or obesity had 3.4 and 53.3 times higher hospitalization rates, respectively, than children without these conditions. Adults in all age groups with obesity, diabetes, coronary artery disease, or congestive heart failure CHF had 1.6–4.7 times, 1.7–7.2 times, 2.0–10.1 times, or 1.7–20.2 times higher hospitalization rates, respectively, than those without these conditions. Adults ≥50 years with asthma had 1.5 to 1.8 times higher hospitalization rates than those without asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The burden of hospitalization with COVID-19 was high, particularly among adults ≥85 years and adults with obesity, diabetes, CAD, or CHF. However, the impact of comorbidities was less in older adults. Population-based incidence rates by age and comorbidities provide more precise estimates of the benefits of vaccines and antiviral medications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Economic and Epidemiological Impact of RSV Hospitalizations in Southern Austria [Southern Austria Respiratory Syncytial Virus INpatient Investigation (ARNI Study)]","authors":"G. Sever Yildiz,&nbsp;E. Resch,&nbsp;V. Strenger,&nbsp;E. Eber,&nbsp;B. Resch","doi":"10.1111/irv.70046","DOIUrl":"10.1111/irv.70046","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>RSV bronchiolitis is a leading cause of hospitalization in infants and young children. We aimed to document the economic burden and epidemiology of RSV over seven seasons in Southern Austria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>All RSV-associated hospitalized (PCR-proven) children ≤ 5 years of age between 1 October 2015 and 30 April 2022 were collected retrospectively. Demographic and epidemiologic data, along with hospitalization costs (direct and indirect), were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 976 children hospitalized due to RSV infection, 87% were healthy term infants, and 79% were &lt; 12 months old. Prematurity (13%) and pre-existing conditions (11%) significantly impacted older children—59% of cases in the 2nd compared with 68% in the 1st year of live. RSV-related hospital costs were approximately €2.0 millions per year (of a total of 60 millions per year). RSV accounted for 19% of hospitalizations due to acute respiratory illness (ARI) in children ≤ 5 years, 37% of all ARI &lt; 6 months, 28% of all ARI &lt; 12 and 6.3% of all-cause hospitalizations &lt; 12 months of age, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Every 5th hospitalization due to respiratory illness in children ≤ 5 years of age was associated with RSV, representing 7.9% of all hospitalizations and 3.3% of all paediatric hospitalization costs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain’","authors":"","doi":"10.1111/irv.70043","DOIUrl":"10.1111/irv.70043","url":null,"abstract":"<p>Mazagatos, C., Mendioroz, J., Rumayor, M., Gallardo García, V., Álvarez Río, V., Cebollada Gracia, A., Batalla Rebollo, N., Barranco Boada, M., Pérez-Martínez, O., Lameiras Azevedo, A., López González-Coviella, N., Castrillejo, D., Fernández Ibáñez, A., Giménez Duran, J., Ramírez Córcoles, C., Ramos Marín, V., Larrauri, A., Monge, S. and (2024), Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children &lt; 1 Year, Weeks 40, 2023, to 8, 2024, Spain. <i>Influenza Other Respi Viruses</i>, 18: e13294. https://doi.org/10.1111/irv.13294</p><p>In the article, there was an error in the denominators reported by one of the regions contributing to the national SiVIRA surveillance, affecting both the primary care and hospital catchment populations. This error affects the calculation of national SARI hospitalisation rates for the 2022–2023 and 2023–2024 seasons, as well as all subsequent estimates of RSV-specific proxy hospitalisation rates and the observed and expected number of RSV hospitalisations. Although Figures 1 and 2 and the published estimates in Table 1 have changed, this correction does not change the overall study conclusions.</p><p>The corrected Table 1 is as follows:</p><p>The corrected Figures 1 and 2 are as follows:</p><p>The text should be corrected every time these estimates are mentioned: In Section 2.3, ‘Estimated Impact of Nirsevimab: Comparing Observed and Expected’, the text in the second paragraph ‘We estimated that, during weeks 40/2023 to 8/2024, the administration of nirsevimab reduced RSV hospitalisations in &lt; 1-year-olds by between 74% and 75%, depending on the scaling factor used. This resulted in between 9364 and 9875 averted RSV hospitalisations in this group and period’ was incorrect and should read as ‘We estimated that, during weeks 40/2023 to 8/2024, the administration of nirsevimab reduced RSV hospitalisations in &lt; 1-year-olds by between 71% and 77%, depending on the scaling factor used. This resulted in between 7510 and 10,213 averted RSV hospitalisations in this group and period’.</p><p>In the discussion section, fourth paragraph, the text ‘Our study has estimated a 74%–75% relative reduction in the risk of RSV hospitalisation …’ was incorrect and should read as ‘Our study has estimated a 71%–77% relative reduction in the risk of RSV hospitalisation …’.</p><p>We apologise for this error.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden of Seasonal Influenza and Its Potential Complications Among Older Japanese Adults: A Real-World Database Study","authors":"Takeshi Arashiro,&nbsp;Yuki Tajima,&nbsp;Yohei Ban,&nbsp;Matthew M. Loiacono,&nbsp;Masayo Ideguchi,&nbsp;Caroline de Courville","doi":"10.1111/irv.70032","DOIUrl":"10.1111/irv.70032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Seasonal influenza may lead to severe complications, including respiratory and cardiovascular disease, that result in considerable healthcare resource utilization (HCRU) and mortality, particularly in older individuals. This real-world study assessed the burden of influenza and its potential complications in older Japanese adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective claims database analysis (April 2015 to June 2019) included insured individuals aged ≥ 60 years at the start of four consecutive influenza seasons in Japan (October 1 to April 30). The primary endpoint was the incidence of influenza-related emergency room (ER) and outpatient visits, the incidence of hospitalizations, the probability of 30-day inpatient mortality, and 60-day medical costs of influenza or its potential complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 8,974,708 individuals (43.2% male, mean ± standard deviation age 73.8 ± 8.9 years), 370,430 (4.13%) were diagnosed with influenza. Overall, 17.18 (95% confidence interval [CI] 16.32–18.04) and 3893.53 (3880.87–3906.19) per 100,000 individuals had influenza-related ER and outpatient visits, respectively, and 181.50 (178.71–184.28) per 100,000 individuals were hospitalized for influenza. The incidence of influenza-related ER visits and hospitalizations for influenza or potential complications and the probability of 30-day inpatient mortality increased with age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Seasonal influenza and its potential complications represent a substantial burden that increases with age in Japanese individuals.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023","authors":"Allison Avrich Ciesla,&nbsp;Josephine Mak,&nbsp;Lauren E. Roper,&nbsp;Katherine E. Fleming-Dutra,&nbsp;Zachary R. Smith,&nbsp;Ryan E. Wiegand,&nbsp;Amadea Britton,&nbsp;Joseph Miller,&nbsp;Ruth Link-Gelles","doi":"10.1111/irv.70038","DOIUrl":"10.1111/irv.70038","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case–control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024","authors":"Lore Merdrignac,&nbsp;Charlotte Laniece Delaunay,&nbsp;Nuno Verdasca,&nbsp;Lorena Vega-Piris,&nbsp;Joan O'Donnell,&nbsp;Noémie Sève,&nbsp;Camino Trobajo-Sanmartín,&nbsp;Silke Buda,&nbsp;Mariëtte Hooiveld,&nbsp;Ana Paula Rodrigues,&nbsp;Gergő Túri,&nbsp;Neus Latorre-Margalef,&nbsp;Ivan Mlinarić,&nbsp;Mihaela Lazar,&nbsp;Marine Maurel,&nbsp;Daniel Castrillejo,&nbsp;Charlene Bennett,&nbsp;Marie-Anne Rameix-Welti,&nbsp;Iván Martínez-Baz,&nbsp;Ralf Dürrwald,&nbsp;Adam Meijer,&nbsp;Aryse Melo,&nbsp;Beatrix Oroszi,&nbsp;Tove Samuelsson Hagey,&nbsp;Sanja Kurečić Filipović,&nbsp;Frederika Dijkstra,&nbsp;Veronica Gomez,&nbsp;Sabrina Bacci,&nbsp;Marlena Kaczmarek,&nbsp;Esther Kissling,&nbsp;the VEBIS Primary Care Vaccine Effectiveness Group","doi":"10.1111/irv.70009","DOIUrl":"10.1111/irv.70009","url":null,"abstract":"<p>We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017–2018 Season and Reveal Age-Associated Differences in Susceptibility and Antibody-Binding Specificity","authors":"Kangchon Kim,&nbsp;Marcos C. Vieira,&nbsp;Sigrid Gouma,&nbsp;Madison E. Weirick,&nbsp;Scott E. Hensley,&nbsp;Sarah Cobey","doi":"10.1111/irv.70033","DOIUrl":"10.1111/irv.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>For antigenically variable pathogens such as influenza, strain fitness is partly determined by the relative availability of hosts susceptible to infection with that strain compared with others. Antibodies to the hemagglutinin (HA) and neuraminidase (NA) confer substantial protection against influenza infection. We asked if a cross-sectional antibody-derived estimate of population susceptibility to different clades of influenza A (H3N2) could predict the success of clades in the following season.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We collected sera from 483 healthy individuals aged 1 to 90 years in the summer of 2017 and analyzed neutralizing responses to the HA and NA of representative strains using focus reduction neutralization tests (FNRT) and enzyme-linked lectin assays (ELLA). We estimated relative population-average and age-specific susceptibilities to circulating viral clades and compared those estimates to changes in clade frequencies in the following 2017–2018 season.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The clade to which neutralizing antibody titers were lowest, indicating greater population susceptibility, dominated the next season. Titer correlations between viral strains varied by age, suggesting age-associated differences in epitope targeting driven by shared past exposures. Yet substantial unexplained variation remains within age groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study indicates how representative measures of population immunity might improve evolutionary forecasts and inform selective pressures on influenza.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}